Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been assigned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $14.85.

A number of analysts recently weighed in on the stock. TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a report on Monday, March 4th. Guggenheim lifted their target price on Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Truist Financial increased their price target on Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Finally, Canaccord Genuity Group began coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 4,080 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the completion of the sale, the insider now directly owns 154,345 shares in the company, valued at $1,548,080.35. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total value of $931,252.64. Following the completion of the sale, the chief executive officer now directly owns 51,653 shares of the company’s stock, valued at $494,835.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Soleil Boughton sold 4,080 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.03, for a total transaction of $40,922.40. Following the transaction, the insider now owns 154,345 shares in the company, valued at approximately $1,548,080.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 736,191 shares of company stock worth $9,733,700. 31.63% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. GSA Capital Partners LLP raised its stake in shares of Hims & Hers Health by 160.5% in the 1st quarter. GSA Capital Partners LLP now owns 210,965 shares of the company’s stock valued at $3,264,000 after acquiring an additional 129,993 shares in the last quarter. Oak Ridge Investments LLC acquired a new position in Hims & Hers Health during the first quarter valued at approximately $2,066,000. Diversify Advisory Services LLC bought a new position in shares of Hims & Hers Health in the first quarter valued at approximately $701,000. Principal Financial Group Inc. lifted its stake in shares of Hims & Hers Health by 17.9% in the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock worth $258,000 after buying an additional 2,525 shares during the last quarter. Finally, Cornerstone Investment Partners LLC bought a new stake in shares of Hims & Hers Health during the 1st quarter worth $161,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Performance

HIMS opened at $11.26 on Friday. The company has a market capitalization of $2.41 billion, a PE ratio of -102.36 and a beta of 0.97. The stock’s fifty day moving average is $14.01 and its 200-day moving average is $10.25. Hims & Hers Health has a one year low of $5.65 and a one year high of $17.16.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The firm had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. During the same period in the previous year, the business earned ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 47.4% compared to the same quarter last year. On average, equities research analysts forecast that Hims & Hers Health will post 0.11 EPS for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.